Steven Gerard Chilinski - Comment

I am a physician patient with ME/CFS enrolled in the Ampligen cost recovery study and have experienced tremendous clinical benefit with virtually no side effects from the drug. The fellow patients I am with have experienced significant benefits as well. Our physician, Dr Peterson, has said that 70 percent of patients that he selects for the drug experience improvement. He selects those with acute viral onset, elevated RNAase activity, low NK cell function, and viral reactivation (EBV and/orCMV and/or HHV-6) I request that the FDA partner with the NIH and Hemispherx in performing a smaller study involving the subset of patients that Dr. Peterson has identified.